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OBJECTIVE — To determine the association between obesity measures and albuminuria in
adults with type 2 diabetes.
RESEARCH DESIGN AND METHODS — In the Look AHEAD (Action for Health in
Diabetes) Study, BMI and waist circumference were measured among 4,985 participants while
total percent body fat was measured by whole-body DEXA scans among 1,351 participants.
Odds of albuminuria by quartiles of BMI, waist circumference, and percent total body fat were
calculated using logistic regression analysis while adjusting for covariates.
RESULTS — The highest quartile of BMI (odds ratio [OR] 1.72 [95% CI 1.40–2.11]) and
waist circumference (OR 1.75 [95% CI 1.42–2.15]) was signiﬁcantly associated with albumin-
uria compared with the lowest quartile after adjustment for covariates. No associations were
noted between quartiles of percent total body fat and albuminuria in any model.
CONCLUSIONS — Increased BMI and abdominal obesity are associated with albuminuria
in overweight and obese adults with type 2 diabetes.
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D
espite substantial improvements in
bloodpressureandglucosecontrol,
2% of adults develop microalbu-
minuria per year after type 2 diabetes di-
agnosis (1). Lifestyle factors remain an
integral component of cardiovascular
risk reduction, yet treatment and pre-
vention of albuminuria (micro- or mac-
roalbuminuria) have primarily focused
on pharmacologic agents, speciﬁcally
thosewhichblockthereninangiotensin
system. This study examined the asso-
ciationbetweenmeasuresofobesityand
albuminuria among adults who partici-
pated in the Look AHEAD (Action for
Health in Diabetes) Study. We hypoth-
esized that obesity is positively associ-
ated with albuminuria.
RESEARCH DESIGN AND
METHODS— The Look AHEAD
Study is a randomized clinical trial con-
ducted in 16 centers in the U.S., and the
design and methods of this trial have pre-
viously been described (2). The purpose
oftheLookAHEADStudyistodetermine
whether cardiovascular morbidity and
mortalityinthosewithtype2diabetescan
be reduced through an intensive lifestyle
intervention aimed at producing and
maintaining weight loss. To address this,
participants are randomized to an inten-
sive lifestyle intervention, which includes
moderate-intensityphysicalactivityanda
calorie-reduced diet, or to a support and
education control group. The present
manuscript is based on data collected in
the full cohort before randomization. A
totalof5,145adultswereenrolled;BMIof
5,144 participants was measured, and
4,985 (97%) participants provided a spot
urine sample. A subset of 1,372 partici-
pants underwent baseline whole-body
dual energy X-ray absorptiometry (DEXA)
scans at one of ﬁve clinical study sites,
(3) and albuminuria data were available
for 1,351 participants. Sex-speciﬁc urine
albumin (micrograms per milliliter) to
creatinine (milligrams per milliliter) ra-
tios (ACRs) were used to deﬁne albumin-
uria, including both microalbuminuria
(ACR 17–249 and 25–354 mg/g for
men and women, respectively) and
macroalbuminuria (ACR 250 mg/g in
men and 355 mg/g in women) (4).
Weight was measured in duplicate
on a digital scale. Standing height was
determinedinduplicatewithastandard
stadiometer. Waist circumference was
measured with subjects in light clothing
with a nonmetallic, constant tension tape
placed around the body at the midpoint
betweenthehighestpointoftheiliaccrest
andthelowestpartofthecostalmarginin
the mid-axillary line. Whole-body DEXA
scans were completed using Hologic
QDR4500A densitometers except for the
Boston site (Hologic Delphi A). Cross-
calibration on a standard phantom was
used to determine percent total body fat.
Scans were read and monitored for qual-
ity by the Prevention Sciences Group,
University of California at San Francisco.
Participants weighing greater than 300
lbs were not included in this subset.
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tered questionnaires were used to obtain
self-reported data on personal medical
history and prescription medications.
Seated blood pressure was measured in
duplicate with an automated device and
blood was drawn after an 8-h fast. A1C
was measured by a dedicated ion-
exchange high-performance liquid chro-
matography instrument (Biorad Variant II).
Statistical analysis. Quartiles of BMI,
waist circumference, and percent total
body fat were determined after stratifying
by sex. Multivariate-adjusted odds ratios
[ORs] for albuminuria by quartiles of
BMI,waistcircumference,andpercentto-
tal body fat were calculated using logistic
regression analysis. Several different lo-
gistic regression analyses were performed
so that changes in parameter estimates
with the addition of selected covariates
could be examined. Model 1 adjusted for
age, sex, and race/ethnicity, model 2
added duration of diabetes and A1C, and
model 3 added hypertension and use of
angiotensin-converting enzyme inhibi-
tors or angiotensin receptor blockers. Ef-
fect modiﬁcation by sex was explored by
ﬁtting interaction terms into the full
model.
RESULTS— Baseline characteristics of
the total Look AHEAD participants (5) and
DEXAsubstudyparticipantshavebeenpre-
viously described (3). Among all partici-
pants, 19.2% had microalbuminuria and
2.7% had macroalbuminuria. Substantial
overlap existed between the BMI and waist
circumference quartiles, with 72% of par-
ticipantsinthehighestBMIquartile(38.4
kg/m
2inmenand40.1kg/m
2inwomen)
alsoincludedinthehighestquartileofwaist
circumference (127.0 cm in men and
119.0 cm women). In the subgroup with
DEXA scans, total percent body fat ranged
from 27.6% in men and 39.3% in
womeninthelowestquartileto34.5%in
men and 45.4% in women in the highest
quartile. Among participants in the highest
quartile of total percent body fat, 59 and
47%wereincludedinthehighestquartileof
BMI and waist circumference, respectively.
Table 1 shows the multivariate-adjusted
ORsofalbuminuriabyquartilesofobesity
measures.InModel1,thehighestquartile
of both BMI and waist circumference was
associated with an approximate twofold
increased odds of albuminuria compared
with the lowest quartile. These associa-
tions were reduced after further adjust-
ment for hypertension and use of
angiotensin-converting enzyme inhibi-
tors/angiotensin receptor blockers medi-
cation. In contrast, no signiﬁcant
association was noted between quartiles
ofpercenttotalbodyfatandalbuminuria.
Interaction terms for measures of obesity
and sex were not signiﬁcant in any of the
models.
CONCLUSIONS— Abdominal obe-
sity is associated with albuminuria in
obeseadultswithtype2diabetes,butper-
cent total body fat does not appear to be
associated with albuminuria. The major-
ity of Look AHEAD participants had a
BMI 30 kg/m
2, and 72% of participants
in the highest BMI quartile were also in
the highest waist circumference quartile.
This may explain the similar associations
noted in this study between albuminuria
and BMI and waist circumference. Re-
gression of albuminuria has been associ-
ated with use of renin-angiotensin
system–blocking drugs and tight glyce-
mic control (6). However, moderate
weight loss reduces the metabolic de-
mandsonthekidneyandmayleadtosub-
stantial regression of urine albumin
excretion (7).
The study was limited by the smaller
sample size for total body fat and the lack
of a direct measure of visceral fat. None-
theless, these ﬁndings contribute to exist-
ing data that demonstrate an urgent need
to determine whether behavioral inter-
ventions that reduce abdominal obesity
retard the development and progression
of albuminuria. The Look AHEAD Study
provides an excellent opportunity to
quantify the effects of weight loss and ex-
ercise on measures of obesity and albu-
minuria. Such information may have a
substantial impact for the prevention and
treatment of kidney disease.
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Table 1—Model comparison of adjusted ORs of albuminuria
Model 1 Model 2 Model 3
BMI quartiles (n  4,985)
1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
2 vs. 1 1.38 (1.13–1.68) 1.35 (1.10–1.65) 1.25 (1.02–1.54)
3 vs. 1 1.43 (1.17–1.75) 1.40 (1.13–1.72) 1.28 (1.04–1.58)
4 vs. 1 1.98 (1.63–2.42) 1.93 (1.58–2.36) 1.72 (1.40–2.11)
Waist circumference quartiles
(n  4,985)
1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
2 vs. 1 1.30 (1.06–1.59) 1.25 (1.02–1.55) 1.22 (0.99–1.51)
3 vs. 1 1.61 (1.32–1.97) 1.56 (1.27–1.91) 1.47 (1.19–1.81)
4 vs. 1 2.04 (1.67–2.48) 1.92 (1.57–2.40) 1.75 (1.42–2.15)
% body fat quartiles (n  1,351)
1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
2 vs. 1 1.08 (0.75–1.54) 0.97 (0.67–1.40) 0.94 (0.65–1.37)
3 vs. 1 1.01 (0.70–1.45) 0.93 (0.64–1.35) 0.90 (0.62–1.31)
4 vs. 1 1.07 (0.75–1.54) 1.05 (0.72–1.52) 0.97 (0.67–1.42)
Data are OR (95% CI). Model 1 adjusts for age, sex, and race/ethnicity. Model 2 adjusts for covariates in
model 1, diabetes duration, and A1C. Model 3 adjusts for covariates in models 1 and 2, and presence of
hypertension, systolic blood pressure, and use of angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers.
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